Invectys raises 1.7 million euros more to finance the clinical development of its therapeutic cancer vaccine

Invectys has announced fundraising of an additional 1.7 million euros from its original group of private investors, aiding the company in the clinical trial of its therapeutic anti-cancer vaccine INVAC-1.

This new funding round completes a total of 10 million euros raised by Invectys with its original investors – family offices, business angels and private individuals who have supporting Invectys since its creation back in April 2010 and have remained committed to accelerating its development.

Invectys have new premises and equipment, allowing it to exploit of the newest technologies

At the same time, Invectys announces its move to new and larger premises within the Paris Santé Cochin Biopark in Paris’ 14th arrondissement. Invectys now has at its disposal around 400 m2 of labs for molecular and cellular biology, a P2 facility and offices permitting it to develop its in house products. Invectys has invested in new equipment allowing it to exploit the newest technologies in molecular biology and cellular immunology. The company has reinforced its team bringing it up to 17 strong with 13 devoted to research and development.

Funds will accelerate the clinical development of INVAC-1

“Strengthened by the new funding round, our new laboratories, equipment and new team members, Invectys starts 2015 with excellent prospects” says Dr. Pierre Langlade Demoyen, Invectys’ CEO, “The funds will serve to accelerate the clinical development of INVAC-1, our therapeutic vaccine that targets the telomerase enzyme that is massively expressed by almost all cancer cells and that plays an essential role in uncontrolled tumour proliferation.

“This new funding round shows the renewed confidence of our original investors,” says Abderrahim Lachgar, Invectys’ Chief Operating Officer. “To be able to raise 10 million euros among the same group of investors is a superb story and shows their commitment to Invectys’ technology and products as we go in to our phase I clinical trial with confidence”.

To learn more about Invectys, please visit www.invectys.com.